cleveland clinic glp-1 Semaglutide Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes Bariatric Surgery vs GLP-1's: Cleveland

Abstract Background: Neuropathic pain is a chronic and often disabling condition that remains refractory to monotherapy because of limited efficacy and dose-limiting adverse effects

The main issues about GLP-1 use as a treatment are its short half-life (around 1 2 min) and the fact that its administration in high doses causes gastrointestinal complications such as nausea, vomiting and diarrhea (Baggio & Drucker, 2002

So, theres a significant unmet need and obesity management medications can offer healthcare providers an option to have an impact on patients

The decrease of SCFAs can lead to intestinal inflammation and the loss of nutrition The most abundant short-chain fatty acids (SCFAs) in the human colon are acetate, propionate, and butyrate, can supply energy to cells in the colon, possess anti-inflammatory properties, and protect epithelial barrier integrity [138140]

These trials should follow standardized dosing, objective endpoints, and rigorous safety protocols